FDA Grants Breakthrough Therapy Designation to Investigational Hepatitis D Treatment
Source: Pixabay.com

FDA Grants Breakthrough Therapy Designation to Investigational Hepatitis D Treatment

According to a press release from Eiger Biopharmaceuticals, the American Food and Drug Administration (FDA) recently granted the Company's experimental hepatitis delta virus drug (hepatitis D), peginterferon lambda, breakthrough therapy…

Continue Reading FDA Grants Breakthrough Therapy Designation to Investigational Hepatitis D Treatment
Study Finds That Denosumab can Boost Bone Density in Primary Biliary Cholangitis and Autoimmune Hepatitis
Free-Photos / Pixabay

Study Finds That Denosumab can Boost Bone Density in Primary Biliary Cholangitis and Autoimmune Hepatitis

According to a story from Healio, a recent study has illustrated that the drug denosumab can improve the bone density of patients with primary biliary cholangitis (PBC) and autoimmune hepatitis…

Continue Reading Study Finds That Denosumab can Boost Bone Density in Primary Biliary Cholangitis and Autoimmune Hepatitis
Young South African Boy with Alternating Hemiplegia of Childhood Receives Successful Treatment
source: pixabay.com

Young South African Boy with Alternating Hemiplegia of Childhood Receives Successful Treatment

  There is a little boy in South Africa who is the only one in the country to be reported to have the ultra-rare neurodevelopmental disorder called alternating hemiplegia of…

Continue Reading Young South African Boy with Alternating Hemiplegia of Childhood Receives Successful Treatment
Synlogic Halts Development of Investigational Hyperammonemia Treatment SYNB1020
Bru-nO / Pixabay

Synlogic Halts Development of Investigational Hyperammonemia Treatment SYNB1020

According to a press release from Synlogic Therapeutics, the Company recently halted development of its investigational hyperammonemia treatment SYNB1020 after an unsuccessful phase 1/2 clinical study. About Hyperammonemia Hyperammonemia is…

Continue Reading Synlogic Halts Development of Investigational Hyperammonemia Treatment SYNB1020
ICYMI: Unique Trial Design for Glioblastoma Could Lead to Numerous New Therapies
source: pixabay.com

ICYMI: Unique Trial Design for Glioblastoma Could Lead to Numerous New Therapies

Glioblastoma  Glioblastoma is a rare type of brain cancer. Sadly, it is the most aggressive form. The median life expectancy for the disease is between 11 and 15 months and…

Continue Reading ICYMI: Unique Trial Design for Glioblastoma Could Lead to Numerous New Therapies
Learn About the Mysterious Mal de Debarquement Syndrome, Which Affects 10,000 Australians
pixel2013 / Pixabay

Learn About the Mysterious Mal de Debarquement Syndrome, Which Affects 10,000 Australians

According to a story from abc.net.au, an unusual and poorly known rare disease has been making its presence known in the country of Australia. This disease is called mal de…

Continue Reading Learn About the Mysterious Mal de Debarquement Syndrome, Which Affects 10,000 Australians
Study Focuses on Muscle Weakness in Patients with Charcot-Marie-Tooth Disease Type 1A
Pezibear / Pixabay

Study Focuses on Muscle Weakness in Patients with Charcot-Marie-Tooth Disease Type 1A

According to a story from Charcot-Marie-Tooth News, a recent study has revealed that patients with Charcot-Marie-Tooth disease (CMT) type 1A still display signs of muscle weakness even if they retain…

Continue Reading Study Focuses on Muscle Weakness in Patients with Charcot-Marie-Tooth Disease Type 1A
Close Menu